Related Experiment Video
Updated: Jan 14, 2026
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Hospital-Based Surveillance of Pediatric Invasive Pneumococcal Diseases, 2016-2023 in Korea: Serotype Trends and
Dayun Kang1, Ki Wook Yun1,2, Hyunju Lee2,3
1Department of Pediatrics, Seoul National University Hospital, Seoul, Korea.
Insights
Pneumococcal conjugate vaccines (PCVs) are crucial for protecting children. This study analyzed invasive pneumococcal disease serotypes in Korean children, revealing significant contributions from non-PCV13 serotypes to guide optimal vaccination strategies.
Area of Science:
- Pediatric infectious diseases
- Vaccinology
- Epidemiology
Background:
- South Korea introduced 10-valent and 13-valent pneumococcal conjugate vaccines (PCVs) into its national immunization program (NIP) in 2014.
- In 2024, PCV15 replaced PCV10 in the NIP, and PCV20 was licensed, necessitating updated serotype distribution data for children.
- Understanding the current landscape of invasive pneumococcal diseases (IPDs) in children is vital for informing vaccination policies.
Purpose of the Study:
- To analyze the current distribution of pneumococcal serotypes causing invasive pneumococcal diseases (IPDs) in children in Korea.
- To provide data to inform optimal vaccination strategies and policy decisions regarding pneumococcal conjugate vaccines (PCVs).
Main Methods:
- A prospective hospital-based surveillance study collected IPD cases from children under 19 years of age across 20 hospitals from 2016 to 2023.
- Changes in IPD case numbers and serotype distribution were compared between the pre-COVID-19 (2016-2019) and during/post-COVID-19 (2020-2023) periods.
Main Results:
- Among 187 cases with determined serotypes, the most frequent were 10A (21.9%), 15C (11.8%), 15A (9.1%), 15B (8.0%), 19A (7.5%), and 23B (5.9%).
- Compared to the pre-COVID-19 period, serotype 10A decreased (27.4% vs. 12.9%), while serotypes 23B (0.9% vs. 14.3%) and 6C (0.9% vs. 7.1%) increased.
- Non-PCV13 serotypes accounted for a substantial proportion of IPDs, with PCV20 unique serotypes comprising 35.3% and non-PCV20 serotypes 36.4%.
Conclusions:
- The study highlights the significant role of non-PCV13 serotypes in pediatric IPDs in Korea.
- These findings offer critical insights for developing effective vaccination strategies to protect children against pneumococcal diseases, especially with the introduction of PCV15 and PCV20.
Background:
In Korea, the 10-valent and 13-valent pneumococcal conjugate vaccines (PCVs) were introduced into the national immunization program (NIP) in 2014 for the protection in children. A decade later, in 2024, PCV15 replaced PCV10 and was included in the NIP in April, while PCV20 was licensed for use in October. To inform optimal vaccination policy, this study aimed to analyze the current distribution of serotypes responsible for invasive pneumococcal diseases (IPDs) in children.
Methods:
IPD cases from children under 19 years of age were collected from a prospective hospital-based surveillance study conducted at 20 hospitals between 2016 and 2023. Data on the changes in IPD case number and serotype distribution were compared between the pre- coronavirus disease 2019 (COVID-19) period (2016-2019) and the during/post-COVID-19 period (2020-2023).
Results:
Of the 187 cases with a determined serotype, the most frequent serotypes identified were 10A (21.9%), 15C (11.8%), 15A (9.1%), 15B (8.0%), and 19A (7.5%), and 23B (5.9%). Compared to the pre-COVID-19 period, the proportion of serotype 10A decreased (27.4% vs. 12.9%), while serotypes 23B (0.9% vs. 14.3%) and 6C (0.9% vs. 7.1%) increased. In regard to the vaccine serotype, PCV13 serotypes accounted for 12.3%, PCV15/PCV20 common serotypes for 3.2%, and PCV20 unique serotypes for 35.3% of IPD cases. Serotype 15C, cross protected by the 15B conjugate vaccines, accounted for 11.8%, and non-PCV20 serotypes for 36.4%.
Conclusion:
Given the approval of two new PCVs, the study results identified the substantial contribution of non-PCV13 serotypes to pediatric IPD and provide critical insights for optimal vaccination strategies to protect children against pneumococcal diseases.
Related Concept Videos
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:22Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia III: Complications and Assessment
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:51Vaccinations